The JAKPPPOT study is investigating whether it is practical and acceptable to use a new group of drugs, called janus kinase inhibitors, to treat palmoplantar pustulosis. These drugs are being used to treat eczema and psoriasis, and there is early evidence that they might be effective in treating palmoplantar pustulosis. The findings of this study will be used to design a larger study to look at the effectiveness of this treatment for palmoplantar pustulosis.

Participants will be asked to take a janus kinase inhibitor called upadacitinib. They will take a tablet once a day for 8 weeks, and have regular clinic reviews and safety blood tests during the trial. We will also interview participants before and after the trial to understand their perspectives on the drug. This is a single-arm study, meaning everyone who participates will receive the active drug. There is no placebo group and there is no randomisation involved.

This trial is only being run at Guy’s and St Thomas’ NHS Foundation Trust.

Anyone with palmoplantar pustulosis that has been present for at least 6 months and is at least moderate in severity can take part. You must be over the age of 18 and cannot be pregnant or breast-feeding.

For more information, please contact the study team at JAKPPPOT@gstt.nhs.uk